Press releases and news
2023
Change in number of shares and votes in Camurus
Exercise of Camurus’ subscription warrant program 2020/2023
Camurus’ Interim Report Second Quarter 2023
Camurus announces new Phase 3 data reinforcing long-term safety and efficacy of octreotide SC depot (CAM2029) in patients with acromegaly
Camurus’ octreotide SC depot (CAM2029) achieves superior treatment response compared to placebo in Phase 3 acromegaly trial
Camurus accepted as participant of the United Nations Global Compact
Change in number of shares and votes in Camurus
Camurus to present at Jefferies 2023 Healthcare Conference New York
Camurus announces FDA approval of Brixadi™ for the treatment of moderate to severe opioid use disorder
Resolutions at the annual general meeting 2023 in Camurus
Camurus’ Interim Report January-March 2023
Camurus appoints Alberto Pedroncelli as Chief Medical Officer
Notice of annual general meeting 2023 in Camurus AB (publ)
Camurus Annual Report for 2022
Camurus’ Full Year Report 2022
Camurus withdraws variation application for CAM2038 to include chronic pain
2022
Change in number of shares and votes in Camurus
Camurus announces PDUFA date for Brixadi™ NDA for the treatment of opioid use disorder in the US
Camurus announces that Braeburn resubmits NDA for Brixadi™ in the US
Camurus to present at Jefferies 2022 Healthcare Conference London
Get the latest news from Camurus
Subscribe to receive latest news from Camurus directly to your email.